Literature DB >> 22446122

Alterations in bacterial spectrum and increasing resistance rates in isolated microorganisms from device-associated infections in an intensive care unit of a teaching hospital in Istanbul (2004-2010).

Asuman Inan1, Asu Ozgultekin, Seniha Senbayrak Akcay, Derya Ozturk Engin, Guldem Turan, Nurgul Ceran, Emine Dincer, Sebahat Aksaray, Pasa Goktas, Ilknur Erdem.   

Abstract

The aim of the present study was to determine the rate of device-associated infection (DAI) and the change in profiles and antimicrobial resistance patterns of the causative microorganisms in a medical-surgical intensive care unit (ICU), as well as to evaluate the effect of a new nationwide hospital infection control program (NHICP), which has been implemented in Turkey. In this study, 5,772 patients that were hospitalized for a total of 43,658 days acquired 1,321 DAIs, with an overall rate of 30.2% per 1,000 ICU days. Between 2004 (before the NHICP) and 2010, the incidence densities of catheter-associated urinary tract infection (CAUTI) decreased from 10.2 to 5.7 per 1,000 device-days (P < 0.0001), and central venous catheter-associated bloodstream infection (CVC-BSI) decreased from 5.3 to 2.1 per 1,000 device-days (P < 0.0001). However, ventilator-associated pneumonia increased from 27.0 to 31.5 per 1,000 device-days. Multidrug-resistant species rates increased from 5.8% to 76.6% (P < 0.0001) for Acinetobacter spp. and from 6.8% to 53.1% (P < 0.0001) for Pseudomonas aeruginosa. The extended-spectrum β-lactamase-producing Enterobacteriaceae rate increased from 23.1% to 54.2% (P = 0.01); the vancomycin-resistance rate among Enterococcus spp. increased from 0% in 2004 to 12.5% in 2010 (P = 0.0003). In conclusion, while a significant decrease was achieved in the incidences of CAUTI and CVC-BSI, the NHICP was not completely effective in our ICU. The high incidence of DAI and the increasing prevalence of multidrug-resistant microorganisms indicate that further interventions are urgently needed.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22446122

Source DB:  PubMed          Journal:  Jpn J Infect Dis        ISSN: 1344-6304            Impact factor:   1.362


  4 in total

1.  The features of infectious diseases departments and anti-infective practices in France and Turkey: a cross-sectional study.

Authors:  H Erdem; J P Stahl; A Inan; S Kilic; M Akova; C Rioux; I Pierre; A Canestri; E Haustraete; D O Engin; E Parlak; X Argemi; D Bruley; E Alp; S Greffe; S Hosoglu; S Patrat-Delon; Y Heper; M Tasbakan; V Corbin; M Hopoglu; I I Balkan; B Mutlu; E Demonchy; H Yilmaz; C Fourcade; L Toko-Tchuindzie; S Kaya; A Engin; A Yalci; C Bernigaud; H Vahaboglu; E Curlier; D Akduman; A Barrelet; S Oncu; V Korten; G Usluer; H Turgut; A Sener; O Evirgen; N Elaldi; L Gorenek
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-05-01       Impact factor: 3.267

2.  [Evolution of antibiotic resistance of Enterobacteriaceae isolated at the Douala General Hospital from 2005 to 2012].

Authors:  Cécile Okalla Ebongue; Martial Dongmo Tsiazok; Jean Pierre Nda Mefo'o; Guy Pascal Ngaba; Gérard Beyiha; Dieudonné Adiogo
Journal:  Pan Afr Med J       Date:  2015-03-12

3.  International Nosocomial Infection Control Consortium (INICC) national report on device-associated infection rates in 19 cities of Turkey, data summary for 2003-2012.

Authors:  Hakan Leblebicioglu; Nurettin Erben; Victor Daniel Rosenthal; Begüm Atasay; Ayse Erbay; Serhat Unal; Gunes Senol; Ayse Willke; Asu Özgültekin; Nilgün Altin; Mehmet Bakir; Oral Oncul; Gülden Ersöz; Davut Ozdemir; Ata Nevzat Yalcin; Halil Özdemir; Dinçer Yıldızdaş; Iftihar Koksal; Canan Aygun; Fatma Sirmatel; Alper Sener; Nazan Tuna; Özay Arikan Akan; Huseyin Turgut; A Pekcan Demiroz; Tanil Kendirli; Emine Alp; Cengiz Uzun; Sercan Ulusoy; Dilek Arman
Journal:  Ann Clin Microbiol Antimicrob       Date:  2014-11-18       Impact factor: 3.944

4.  Hospital-acquired infections caused by enterococci: a systematic review and meta-analysis, WHO European Region, 1 January 2010 to 4 February 2020.

Authors:  Simon Brinkwirth; Olaniyi Ayobami; Tim Eckmanns; Robby Markwart
Journal:  Euro Surveill       Date:  2021-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.